CureVac NV (CVAC)
5.135
-0.08
(-1.44%)
USD |
NASDAQ |
Dec 09, 16:00
5.135
0.00 (0.00%)
After-Hours: 16:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 1.156B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 68.06% |
| Valuation | |
| PE Ratio | 7.186 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 14.26 |
| Price to Book Value | 1.130 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.0403 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 98.30% |
Profile
| CureVac BV is a clinical-stage biopharmaceutical company, which engages in developing transformative medicines based on messenger ribonucleic acid (mRNA). Its product portfolio includes clinical and preclinical candidates across multiple disease indications in prophylactic vaccines, oncology, and protein therapy. The company was founded by Ingmar Hoerr and Florian von der Mülbe in 2000 and is headquartered in Tübingen, Germany. |
| URL | http://www.curevac.com |
| Investor Relations URL | https://www.curevac.com/en/investor-relations/ |
| HQ State/Province | Baden Wuerttemberg |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | Apr. 09, 2026 (est.) |
| Last Earnings Release | Nov. 12, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| CureVac BV is a clinical-stage biopharmaceutical company, which engages in developing transformative medicines based on messenger ribonucleic acid (mRNA). Its product portfolio includes clinical and preclinical candidates across multiple disease indications in prophylactic vaccines, oncology, and protein therapy. The company was founded by Ingmar Hoerr and Florian von der Mülbe in 2000 and is headquartered in Tübingen, Germany. |
| URL | http://www.curevac.com |
| Investor Relations URL | https://www.curevac.com/en/investor-relations/ |
| HQ State/Province | Baden Wuerttemberg |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | Apr. 09, 2026 (est.) |
| Last Earnings Release | Nov. 12, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |